Trial Outcomes & Findings for A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (NCT NCT04632992)
NCT ID: NCT04632992
Last Updated: 2025-01-08
Results Overview
Confirmed objective response rate (cORR)=percentage of participants with best response as complete response (CR) or partial response (PR) for measurable disease \& CR for non-measurable disease. Confirmation=CR/PR on 2 consecutive visits ≥4 weeks apart for 3-week cycles \& ≥6 weeks apart for 4-week cycles. Per RECIST, CR=disappearance of all target lesions. PR= ≥30% decrease in sum of diameters of target lesions, in absence of CR. Per RANO, CR=complete disappearance of all measurable \& non-measurable disease for ≥4 weeks; no new lesions/abnormality on T2/FLAIR imaging; stable/improved non-enhancing lesions; participants must be off corticosteroids or on physiological doses; clinical status stable/improved. PR= ≥50% decrease in the sum of products of perpendicular diameters of measurable enhancing lesions on T2/FLAIR imaging for ≥4 weeks; no progression of non-measurable T1 disease; stable/improved non-enhancing lesions; corticosteroid dose ≤ baseline; clinical status stable/improved.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
252 participants
Primary outcome timeframe
Up to 32 months
Results posted on
2025-01-08
Participant Flow
A total of 252 participants with advanced unresectable or metastatic solid tumors with positive biomarker result took part in the study across 38 investigative sites in the United States.
Participants in this multi-arm study were treated with a drug or drug regimen tailored to their biomarker identified at screening. A total of 15 arms (Arms A to O) were planned for this study. However, no participants were enrolled in Arm A.
Participant milestones
| Measure |
Arm B: Inavolisib (GDC-0077)
Participants with a positive tumor biomarker result for phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) activating mutation self-administered inavolisib 9 milligrams (mg), orally, once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
Arm C: Alectinib
Participants with a positive tumor biomarker result for anaplastic lymphoma kinase (ALK) gene fusion self-administered alectinib, 600 mg, orally, twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm D: Ipatasertib
Participants with a positive tumor biomarker result for phosphatase and tensin homolog (PTEN) loss/loss-of-function or protein kinase B (AKT) activating mutation self-administered ipatasertib, 400 mg orally, QD until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm E: Atezolizumab + Chemotherapy
Participants with a positive tumor biomarker result for tumor mutational burden-high (TMB-H) or microsatellite instability high (MSI-H) or deficient mismatch repair (dMMR) received atezolizumab,1200 mg, as intravenous (IV) infusion, on Day 1 of each 21-day cycle in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine) until disease progression, loss of clinical benefit, or unacceptable toxicity whichever occurs first.
|
Arm F: Trastuzumab Emtansine + Atezolizumab
Participants with a positive tumor biomarker result for human epidermal growth factor receptor 2 (HER2) gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 milligrams/kilograms (mg/kg), as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm G: PH FDC SC
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as subcutaneous (SC) injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2.
|
Arm H: PH FDC SC + Chemotherapy
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2 in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine).
|
Arm I: Trastuzumab Emtansine + Tucatinib
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received trastuzumab emtansine, 3.6 mg/kg as IV infusion, every 21 days in combination with tucatinib, 300 mg, orally, BID starting from Cycle 1 Day 1 until disease progression or unacceptable toxicity, whichever occurs first.
|
Arm J: Trastuzumab Emtansine + Atezolizumab
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation plus TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 mg/kg, as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm K: Ipatasertib + Atezolizumab
Participants with a positive tumor biomarker result for PIK3CA activating mutation received ipatasertib, 400 mg, orally QD in combination with atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm L: Ipatasertib + Atezolizumab
Participants with a positive tumor biomarker result for PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD and received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or intolerable toxicity, whichever occurs first.
|
Arm M: Ipatasertib + Paclitaxel
Participants with a positive tumor biomarker result for co-mutations in PIK3CA activating mutations and PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD on Days 1 to 21 of 28-day cycles and received paclitaxel, 80 milligrams per meter square (mg/m\^2), as IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm N: Atezolizumab + Tiragolumab
Participants with a positive tumor biomarker result for TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by tiragolumab, 600 mg, as IV infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm O: Pralsetinib
Participants with a positive tumor biomarker result for rearranged during transfection (RET) gene fusion self-administered pralsetinib, 400 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
26
|
5
|
26
|
25
|
25
|
13
|
8
|
23
|
19
|
28
|
25
|
3
|
23
|
3
|
|
Overall Study
COMPLETED
|
2
|
3
|
5
|
4
|
5
|
4
|
0
|
5
|
3
|
4
|
5
|
1
|
6
|
1
|
|
Overall Study
NOT COMPLETED
|
24
|
2
|
21
|
21
|
20
|
9
|
8
|
18
|
16
|
24
|
20
|
2
|
17
|
2
|
Reasons for withdrawal
| Measure |
Arm B: Inavolisib (GDC-0077)
Participants with a positive tumor biomarker result for phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) activating mutation self-administered inavolisib 9 milligrams (mg), orally, once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
Arm C: Alectinib
Participants with a positive tumor biomarker result for anaplastic lymphoma kinase (ALK) gene fusion self-administered alectinib, 600 mg, orally, twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm D: Ipatasertib
Participants with a positive tumor biomarker result for phosphatase and tensin homolog (PTEN) loss/loss-of-function or protein kinase B (AKT) activating mutation self-administered ipatasertib, 400 mg orally, QD until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm E: Atezolizumab + Chemotherapy
Participants with a positive tumor biomarker result for tumor mutational burden-high (TMB-H) or microsatellite instability high (MSI-H) or deficient mismatch repair (dMMR) received atezolizumab,1200 mg, as intravenous (IV) infusion, on Day 1 of each 21-day cycle in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine) until disease progression, loss of clinical benefit, or unacceptable toxicity whichever occurs first.
|
Arm F: Trastuzumab Emtansine + Atezolizumab
Participants with a positive tumor biomarker result for human epidermal growth factor receptor 2 (HER2) gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 milligrams/kilograms (mg/kg), as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm G: PH FDC SC
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as subcutaneous (SC) injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2.
|
Arm H: PH FDC SC + Chemotherapy
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2 in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine).
|
Arm I: Trastuzumab Emtansine + Tucatinib
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received trastuzumab emtansine, 3.6 mg/kg as IV infusion, every 21 days in combination with tucatinib, 300 mg, orally, BID starting from Cycle 1 Day 1 until disease progression or unacceptable toxicity, whichever occurs first.
|
Arm J: Trastuzumab Emtansine + Atezolizumab
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation plus TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 mg/kg, as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm K: Ipatasertib + Atezolizumab
Participants with a positive tumor biomarker result for PIK3CA activating mutation received ipatasertib, 400 mg, orally QD in combination with atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm L: Ipatasertib + Atezolizumab
Participants with a positive tumor biomarker result for PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD and received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or intolerable toxicity, whichever occurs first.
|
Arm M: Ipatasertib + Paclitaxel
Participants with a positive tumor biomarker result for co-mutations in PIK3CA activating mutations and PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD on Days 1 to 21 of 28-day cycles and received paclitaxel, 80 milligrams per meter square (mg/m\^2), as IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm N: Atezolizumab + Tiragolumab
Participants with a positive tumor biomarker result for TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by tiragolumab, 600 mg, as IV infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm O: Pralsetinib
Participants with a positive tumor biomarker result for rearranged during transfection (RET) gene fusion self-administered pralsetinib, 400 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Adverse Event
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
Overall Study
Death
|
17
|
1
|
14
|
14
|
13
|
6
|
7
|
12
|
15
|
20
|
8
|
2
|
10
|
1
|
|
Overall Study
Lost to Follow-up
|
1
|
0
|
1
|
0
|
2
|
0
|
1
|
1
|
1
|
1
|
2
|
0
|
0
|
0
|
|
Overall Study
Reason not Specified
|
2
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
Overall Study
Physician Decision
|
0
|
0
|
0
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
|
Overall Study
Progressive Disease
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
2
|
0
|
|
Overall Study
Withdrawal by Subject
|
4
|
1
|
5
|
4
|
3
|
3
|
0
|
5
|
0
|
2
|
8
|
0
|
1
|
1
|
Baseline Characteristics
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
Baseline characteristics by cohort
| Measure |
Arm B: Inavolisib (GDC-0077)
n=26 Participants
Participants with a positive tumor biomarker result for PIK3CA activating mutation self-administered inavolisib 9 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
Arm C: Alectinib
n=5 Participants
Participants with a positive tumor biomarker result for ALK gene fusion self-administered alectinib, 600 mg, orally, BID until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm D: Ipatasertib
n=26 Participants
Participants with a positive tumor biomarker result for phosphatase and tensin homolog (PTEN) loss/loss-of-function or protein kinase B (AKT) activating mutation self-administered ipatasertib, 400 mg orally, QD until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm E: Atezolizumab + Chemotherapy
n=25 Participants
Participants with a positive tumor biomarker result for TMB-H or MSI-H or dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine) until disease progression, loss of clinical benefit, or unacceptable toxicity whichever occurs first.
|
Arm F: Trastuzumab Emtansine + Atezolizumab
n=25 Participants
Participants with a positive tumor biomarker result for human epidermal growth factor receptor 2 (HER2) gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 milligrams/kilograms (mg/kg), as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm G: PH FDC SC
n=13 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as subcutaneous (SC) injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2.
|
Arm H: PH FDC SC + Chemotherapy
n=8 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2 in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine).
|
Arm I: Trastuzumab Emtansine + Tucatinib
n=23 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received trastuzumab emtansine, 3.6 mg/kg as IV infusion, every 21 days in combination with tucatinib, 300 mg, orally, BID starting from Cycle 1 Day 1 until disease progression or unacceptable toxicity, whichever occurs first.
|
Arm J: Trastuzumab Emtansine + Atezolizumab
n=19 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation plus TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 mg/kg, as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm K: Ipatasertib + Atezolizumab
n=28 Participants
Participants with a positive tumor biomarker result for PIK3CA activating mutation received ipatasertib, 400 mg, orally QD in combination with atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm L: Ipatasertib + Atezolizumab
n=25 Participants
Participants with a positive tumor biomarker result for PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD and received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or intolerable toxicity, whichever occurs first.
|
Arm M: Ipatasertib + Paclitaxel
n=3 Participants
Participants with a positive tumor biomarker result for co-mutations in PIK3CA activating mutations and PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD on Days 1 to 21 of 28-day cycles and received paclitaxel, 80 mg/m\^2, as IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm N: Atezolizumab + Tiragolumab
n=23 Participants
Participants with a positive tumor biomarker result for TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by tiragolumab, 600 mg, as IV infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm O: Pralsetinib
n=3 Participants
Participants with a positive tumor biomarker result for RET gene fusion self-administered pralsetinib, 400 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
Total
n=252 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
64.5 years
STANDARD_DEVIATION 11.5 • n=99 Participants
|
62.6 years
STANDARD_DEVIATION 6.7 • n=107 Participants
|
66.7 years
STANDARD_DEVIATION 10.0 • n=206 Participants
|
66.0 years
STANDARD_DEVIATION 12.0 • n=7 Participants
|
66.1 years
STANDARD_DEVIATION 12.9 • n=31 Participants
|
63.8 years
STANDARD_DEVIATION 10.7 • n=30 Participants
|
61.1 years
STANDARD_DEVIATION 12.8 • n=3 Participants
|
64.2 years
STANDARD_DEVIATION 12.0 • n=6 Participants
|
61.8 years
STANDARD_DEVIATION 10.7 • n=114 Participants
|
60.3 years
STANDARD_DEVIATION 10.4
|
59.8 years
STANDARD_DEVIATION 11.4 • n=19 Participants
|
57.7 years
STANDARD_DEVIATION 19.4 • n=4 Participants
|
63.7 years
STANDARD_DEVIATION 11.0 • n=7 Participants
|
71.3 years
STANDARD_DEVIATION 16.2 • n=7 Participants
|
63.6 years
STANDARD_DEVIATION 11.4 • n=3 Participants
|
|
Sex: Female, Male
Female
|
18 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
18 Participants
n=206 Participants
|
11 Participants
n=7 Participants
|
8 Participants
n=31 Participants
|
7 Participants
n=30 Participants
|
5 Participants
n=3 Participants
|
15 Participants
n=6 Participants
|
9 Participants
n=114 Participants
|
19 Participants
|
15 Participants
n=19 Participants
|
2 Participants
n=4 Participants
|
14 Participants
n=7 Participants
|
1 Participants
n=7 Participants
|
146 Participants
n=3 Participants
|
|
Sex: Female, Male
Male
|
8 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
14 Participants
n=7 Participants
|
17 Participants
n=31 Participants
|
6 Participants
n=30 Participants
|
3 Participants
n=3 Participants
|
8 Participants
n=6 Participants
|
10 Participants
n=114 Participants
|
9 Participants
|
10 Participants
n=19 Participants
|
1 Participants
n=4 Participants
|
9 Participants
n=7 Participants
|
2 Participants
n=7 Participants
|
106 Participants
n=3 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
1 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
2 Participants
n=6 Participants
|
1 Participants
n=114 Participants
|
1 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
3 Participants
n=7 Participants
|
0 Participants
n=7 Participants
|
11 Participants
n=3 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
26 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
24 Participants
n=206 Participants
|
24 Participants
n=7 Participants
|
24 Participants
n=31 Participants
|
12 Participants
n=30 Participants
|
6 Participants
n=3 Participants
|
20 Participants
n=6 Participants
|
17 Participants
n=114 Participants
|
26 Participants
|
25 Participants
n=19 Participants
|
3 Participants
n=4 Participants
|
20 Participants
n=7 Participants
|
3 Participants
n=7 Participants
|
235 Participants
n=3 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
2 Participants
n=3 Participants
|
1 Participants
n=6 Participants
|
1 Participants
n=114 Participants
|
1 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=7 Participants
|
6 Participants
n=3 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=3 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
2 Participants
n=6 Participants
|
1 Participants
n=114 Participants
|
0 Participants
|
2 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=7 Participants
|
6 Participants
n=3 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=3 Participants
|
|
Race (NIH/OMB)
Black or African American
|
2 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
4 Participants
n=31 Participants
|
1 Participants
n=30 Participants
|
2 Participants
n=3 Participants
|
1 Participants
n=6 Participants
|
3 Participants
n=114 Participants
|
2 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
4 Participants
n=7 Participants
|
0 Participants
n=7 Participants
|
23 Participants
n=3 Participants
|
|
Race (NIH/OMB)
White
|
24 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
21 Participants
n=206 Participants
|
24 Participants
n=7 Participants
|
20 Participants
n=31 Participants
|
12 Participants
n=30 Participants
|
4 Participants
n=3 Participants
|
20 Participants
n=6 Participants
|
12 Participants
n=114 Participants
|
24 Participants
|
23 Participants
n=19 Participants
|
3 Participants
n=4 Participants
|
19 Participants
n=7 Participants
|
3 Participants
n=7 Participants
|
214 Participants
n=3 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=3 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
2 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
3 Participants
n=114 Participants
|
2 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=7 Participants
|
9 Participants
n=3 Participants
|
PRIMARY outcome
Timeframe: Up to 32 monthsPopulation: Efficacy population included all participants who received at least one dose of study treatment and either had at least one post-baseline tumor assessment or discontinued treatment for any reason. Percentages have been rounded off to the nearest decimal point.
Confirmed objective response rate (cORR)=percentage of participants with best response as complete response (CR) or partial response (PR) for measurable disease \& CR for non-measurable disease. Confirmation=CR/PR on 2 consecutive visits ≥4 weeks apart for 3-week cycles \& ≥6 weeks apart for 4-week cycles. Per RECIST, CR=disappearance of all target lesions. PR= ≥30% decrease in sum of diameters of target lesions, in absence of CR. Per RANO, CR=complete disappearance of all measurable \& non-measurable disease for ≥4 weeks; no new lesions/abnormality on T2/FLAIR imaging; stable/improved non-enhancing lesions; participants must be off corticosteroids or on physiological doses; clinical status stable/improved. PR= ≥50% decrease in the sum of products of perpendicular diameters of measurable enhancing lesions on T2/FLAIR imaging for ≥4 weeks; no progression of non-measurable T1 disease; stable/improved non-enhancing lesions; corticosteroid dose ≤ baseline; clinical status stable/improved.
Outcome measures
| Measure |
Arm B: Inavolisib (GDC-0077)
n=26 Participants
Participants with a positive tumor biomarker result for PIK3CA activating mutation self-administered inavolisib 9 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
Arm C: Alectinib
n=5 Participants
Participants with a positive tumor biomarker result for ALK gene fusion self-administered alectinib, 600 mg, orally, BID until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm D: Ipatasertib
n=26 Participants
Participants with a positive tumor biomarker result for phosphatase and tensin homolog (PTEN) loss/loss-of-function or protein kinase B (AKT) activating mutation self-administered ipatasertib, 400 mg orally, QD until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm E: Atezolizumab + Chemotherapy
n=25 Participants
Participants with a positive tumor biomarker result for TMB-H or MSI-H or dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine) until disease progression, loss of clinical benefit, or unacceptable toxicity whichever occurs first.
|
Arm F: Trastuzumab Emtansine + Atezolizumab
n=25 Participants
Participants with a positive tumor biomarker result for human epidermal growth factor receptor 2 (HER2) gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 milligrams/kilograms (mg/kg), as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm G: PH FDC SC
n=13 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as subcutaneous (SC) injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2.
|
Arm H: PH FDC SC + Chemotherapy
n=8 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2 in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine).
|
Arm I: Trastuzumab Emtansine + Tucatinib
n=23 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received trastuzumab emtansine, 3.6 mg/kg as IV infusion, every 21 days in combination with tucatinib, 300 mg, orally, BID starting from Cycle 1 Day 1 until disease progression or unacceptable toxicity, whichever occurs first.
|
Arm J: Trastuzumab Emtansine + Atezolizumab
n=19 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation plus TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 mg/kg, as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm K: Ipatasertib + Atezolizumab
n=28 Participants
Participants with a positive tumor biomarker result for PIK3CA activating mutation received ipatasertib, 400 mg, orally QD in combination with atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm L: Ipatasertib + Atezolizumab
n=25 Participants
Participants with a positive tumor biomarker result for PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD and received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or intolerable toxicity, whichever occurs first.
|
Arm M: Ipatasertib + Paclitaxel
n=3 Participants
Participants with a positive tumor biomarker result for co-mutations in PIK3CA activating mutations and PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD on Days 1 to 21 of 28-day cycles and received paclitaxel, 80 mg/m\^2, as IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm N: Atezolizumab + Tiragolumab
n=23 Participants
Participants with a positive tumor biomarker result for TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by tiragolumab, 600 mg, as IV infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm O: Pralsetinib
n=3 Participants
Participants with a positive tumor biomarker result for RET gene fusion self-administered pralsetinib, 400 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Confirmed Objective Response Rate (ORR) Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria for Primary Central Nervous System (CNS) Tumors
|
11.5 percentage of participants
Interval 2.4 to 30.2
|
20.0 percentage of participants
Interval 0.5 to 71.6
|
11.5 percentage of participants
Interval 2.4 to 30.2
|
28.0 percentage of participants
Interval 12.1 to 49.4
|
12.0 percentage of participants
Interval 2.5 to 31.2
|
0.0 percentage of participants
Interval 0.0 to 24.7
|
0.0 percentage of participants
Interval 0.0 to 36.9
|
13.0 percentage of participants
Interval 2.8 to 33.6
|
0.0 percentage of participants
Interval 0.0 to 17.6
|
0.0 percentage of participants
Interval 0.0 to 12.3
|
0.0 percentage of participants
Interval 0.0 to 13.7
|
66.7 percentage of participants
Interval 9.4 to 99.2
|
21.7 percentage of participants
Interval 7.5 to 43.7
|
33.3 percentage of participants
Interval 0.8 to 90.6
|
SECONDARY outcome
Timeframe: Time from start of treatment to the first occurrence of disease progression or death from any cause (Up to 32 months)Population: Efficacy population included all participants who received at least one dose of study treatment and either had at least one post-baseline tumor assessment or discontinued treatment for any reason. Participants who did not experience death or disease progression were censored on the day of the last available assessment.
PFS=time from start of treatment to the first occurrence of disease progression (PD) or death from any cause, whichever occurs first, per RECIST v1.1, or RANO. Per RECIST, PD=≥20% increase in sum of diameters of lesions, using the smallest sum during the study as reference, including baseline (BL). Per RANO, PD= ≥25% increase in sum of products of perpendicular diameters of enhancing lesions compared to smallest tumor measurement at BL/best response, on stable/increasing corticosteroids (CS) dose; Significant/ ≥25% increase of T2/FLAIR non-enhancing lesion on stable/increasing CS dose compared to BL/best response after therapy start; Presence of new lesions/increase of enhancement; Clear progression of non-measurable disease; Definite clinical deterioration only due to tumor/decrease in CS dose; Failure to return for evaluation due to death/deterioration. Kaplan-Meier methodology was used to estimate PFS; patients without an event were censored on the last available assessment day.
Outcome measures
| Measure |
Arm B: Inavolisib (GDC-0077)
n=26 Participants
Participants with a positive tumor biomarker result for PIK3CA activating mutation self-administered inavolisib 9 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
Arm C: Alectinib
n=5 Participants
Participants with a positive tumor biomarker result for ALK gene fusion self-administered alectinib, 600 mg, orally, BID until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm D: Ipatasertib
n=26 Participants
Participants with a positive tumor biomarker result for phosphatase and tensin homolog (PTEN) loss/loss-of-function or protein kinase B (AKT) activating mutation self-administered ipatasertib, 400 mg orally, QD until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm E: Atezolizumab + Chemotherapy
n=25 Participants
Participants with a positive tumor biomarker result for TMB-H or MSI-H or dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine) until disease progression, loss of clinical benefit, or unacceptable toxicity whichever occurs first.
|
Arm F: Trastuzumab Emtansine + Atezolizumab
n=25 Participants
Participants with a positive tumor biomarker result for human epidermal growth factor receptor 2 (HER2) gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 milligrams/kilograms (mg/kg), as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm G: PH FDC SC
n=13 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as subcutaneous (SC) injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2.
|
Arm H: PH FDC SC + Chemotherapy
n=8 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2 in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine).
|
Arm I: Trastuzumab Emtansine + Tucatinib
n=23 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received trastuzumab emtansine, 3.6 mg/kg as IV infusion, every 21 days in combination with tucatinib, 300 mg, orally, BID starting from Cycle 1 Day 1 until disease progression or unacceptable toxicity, whichever occurs first.
|
Arm J: Trastuzumab Emtansine + Atezolizumab
n=19 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation plus TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 mg/kg, as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm K: Ipatasertib + Atezolizumab
n=28 Participants
Participants with a positive tumor biomarker result for PIK3CA activating mutation received ipatasertib, 400 mg, orally QD in combination with atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm L: Ipatasertib + Atezolizumab
n=25 Participants
Participants with a positive tumor biomarker result for PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD and received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or intolerable toxicity, whichever occurs first.
|
Arm M: Ipatasertib + Paclitaxel
n=3 Participants
Participants with a positive tumor biomarker result for co-mutations in PIK3CA activating mutations and PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD on Days 1 to 21 of 28-day cycles and received paclitaxel, 80 mg/m\^2, as IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm N: Atezolizumab + Tiragolumab
n=23 Participants
Participants with a positive tumor biomarker result for TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by tiragolumab, 600 mg, as IV infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm O: Pralsetinib
n=3 Participants
Participants with a positive tumor biomarker result for RET gene fusion self-administered pralsetinib, 400 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
|
4.24 months
Interval 1.84 to 8.08
|
4.98 months
Interval 1.54 to
The upper limit of the 95% confidence interval (CI) was not estimable because there was an insufficient number of events.
|
3.48 months
Interval 1.87 to 6.47
|
3.94 months
Interval 2.17 to 8.38
|
4.73 months
Interval 2.07 to 10.22
|
2.46 months
Interval 1.77 to 5.16
|
3.02 months
Interval 1.54 to 5.52
|
2.69 months
Interval 1.94 to 6.18
|
1.87 months
Interval 1.71 to 2.2
|
2.10 months
Interval 1.64 to 3.48
|
3.61 months
Interval 2.33 to 6.34
|
5.98 months
Interval 1.28 to
The upper limit of the 95% CI was not estimable because there was an insufficient number of events.
|
4.76 months
Interval 1.87 to 16.43
|
7.10 months
Interval 1.84 to
The upper limit of the 95% CI was not estimable because there was an insufficient number of events.
|
SECONDARY outcome
Timeframe: Time from the date of the first confirmed CR/PR to PD or death from any cause (Up to 32 months)Population: Efficacy population included all participants who received at least one dose of study treatment and either had at least one post-baseline tumor assessment or discontinued treatment for any reason. Participants who achieved a confirmed CR/PR were analyzed for this outcome measure.
DOR was defined as the time from the date of the first confirmed complete response (CR) or partial response (PR) to disease progression (PD) or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1 or RANO. CR \& PR were defined per RECIST or RANO as outlined in the description for the cORR outcome measure (OM). PD was defined per RECIST or RANO as outlined in the description for the PFS OM. Kaplan-Meier methodology was used to estimate the median DOR. The 95% confidence intervals for the median DOR were computed by the method of Brookmeyer and Crowley. Participants who did not experience death or PD were censored on the day of the last available assessment.
Outcome measures
| Measure |
Arm B: Inavolisib (GDC-0077)
n=3 Participants
Participants with a positive tumor biomarker result for PIK3CA activating mutation self-administered inavolisib 9 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
Arm C: Alectinib
n=1 Participants
Participants with a positive tumor biomarker result for ALK gene fusion self-administered alectinib, 600 mg, orally, BID until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm D: Ipatasertib
n=3 Participants
Participants with a positive tumor biomarker result for phosphatase and tensin homolog (PTEN) loss/loss-of-function or protein kinase B (AKT) activating mutation self-administered ipatasertib, 400 mg orally, QD until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm E: Atezolizumab + Chemotherapy
n=7 Participants
Participants with a positive tumor biomarker result for TMB-H or MSI-H or dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine) until disease progression, loss of clinical benefit, or unacceptable toxicity whichever occurs first.
|
Arm F: Trastuzumab Emtansine + Atezolizumab
n=3 Participants
Participants with a positive tumor biomarker result for human epidermal growth factor receptor 2 (HER2) gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 milligrams/kilograms (mg/kg), as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm G: PH FDC SC
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as subcutaneous (SC) injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2.
|
Arm H: PH FDC SC + Chemotherapy
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2 in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine).
|
Arm I: Trastuzumab Emtansine + Tucatinib
n=3 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received trastuzumab emtansine, 3.6 mg/kg as IV infusion, every 21 days in combination with tucatinib, 300 mg, orally, BID starting from Cycle 1 Day 1 until disease progression or unacceptable toxicity, whichever occurs first.
|
Arm J: Trastuzumab Emtansine + Atezolizumab
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation plus TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 mg/kg, as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm K: Ipatasertib + Atezolizumab
Participants with a positive tumor biomarker result for PIK3CA activating mutation received ipatasertib, 400 mg, orally QD in combination with atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm L: Ipatasertib + Atezolizumab
Participants with a positive tumor biomarker result for PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD and received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or intolerable toxicity, whichever occurs first.
|
Arm M: Ipatasertib + Paclitaxel
n=2 Participants
Participants with a positive tumor biomarker result for co-mutations in PIK3CA activating mutations and PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD on Days 1 to 21 of 28-day cycles and received paclitaxel, 80 mg/m\^2, as IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm N: Atezolizumab + Tiragolumab
n=5 Participants
Participants with a positive tumor biomarker result for TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by tiragolumab, 600 mg, as IV infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm O: Pralsetinib
n=1 Participants
Participants with a positive tumor biomarker result for RET gene fusion self-administered pralsetinib, 400 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
|
5.6 months
Interval 5.3 to
The upper limit of the 95% CI was not estimable because there was an insufficient number of events.
|
6.5 months
The 95% CI was not estimable because only one participant had confirmed response, but the median was estimable because the participant had experienced an event.
|
5.5 months
Interval 3.7 to
The upper limit of the 95% CI was not estimable because there was an insufficient number of events.
|
NA months
Interval 7.4 to
The median and upper limit of the 95% CI was not estimable because there was an insufficient number of events.
|
20.0 months
The 95% CI was not estimable because there was an insufficient number of events.
|
—
|
—
|
7.6 months
Interval 3.7 to
The upper limit of the 95% CI was not estimable because there was an insufficient number of events.
|
—
|
—
|
—
|
5.5 months
Interval 4.0 to
The upper limit of the 95% CI was not estimable because there was an insufficient number of events.
|
NA months
Interval 3.6 to
The median and upper limit of the 95% CI was not estimable because there was an insufficient number of events.
|
NA months
The median and 95% CI were not estimable because only one participant had confirmed response and the participant had not experienced an event (i.e., censored).
|
SECONDARY outcome
Timeframe: At Months 3, 6, 9 and 12Population: Efficacy population included all participants who received at least one dose of study treatment and either had at least one post-baseline tumor assessment or discontinued treatment for any reason. The number analyzed per timepoint is the number of participants (out of the overall number of participants analyzed for PFS per arm) who remained at risk for a PFS event at that timepoint. Different participants may have contributed data for each timepoint.
The PFS rates were calculated using the Kaplan-Meier (KM) method to estimate the percent survival probability of participants (i.e., PFS event-free: did not experience PD or death from any cause) in each treatment arm at landmark timepoints. The 95% confidence intervals for each PFS rate were computed by the method of Greenwood. PFS was defined as the time from the start of study treatment to the first occurrence of PD or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1 or RANO. PD was defined per RECIST or RANO as outlined in the description for the PFS OM. Participants who did not experience death or PD were censored on the day of the last available assessment. The number analyzed per landmark timepoint actually represents the number of participants who remained at risk of experiencing a PFS event at that timepoint. Percentages are rounded off to the nearest decimal point.
Outcome measures
| Measure |
Arm B: Inavolisib (GDC-0077)
n=26 Participants
Participants with a positive tumor biomarker result for PIK3CA activating mutation self-administered inavolisib 9 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
Arm C: Alectinib
n=5 Participants
Participants with a positive tumor biomarker result for ALK gene fusion self-administered alectinib, 600 mg, orally, BID until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm D: Ipatasertib
n=26 Participants
Participants with a positive tumor biomarker result for phosphatase and tensin homolog (PTEN) loss/loss-of-function or protein kinase B (AKT) activating mutation self-administered ipatasertib, 400 mg orally, QD until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm E: Atezolizumab + Chemotherapy
n=25 Participants
Participants with a positive tumor biomarker result for TMB-H or MSI-H or dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine) until disease progression, loss of clinical benefit, or unacceptable toxicity whichever occurs first.
|
Arm F: Trastuzumab Emtansine + Atezolizumab
n=25 Participants
Participants with a positive tumor biomarker result for human epidermal growth factor receptor 2 (HER2) gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 milligrams/kilograms (mg/kg), as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm G: PH FDC SC
n=13 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as subcutaneous (SC) injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2.
|
Arm H: PH FDC SC + Chemotherapy
n=8 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2 in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine).
|
Arm I: Trastuzumab Emtansine + Tucatinib
n=23 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received trastuzumab emtansine, 3.6 mg/kg as IV infusion, every 21 days in combination with tucatinib, 300 mg, orally, BID starting from Cycle 1 Day 1 until disease progression or unacceptable toxicity, whichever occurs first.
|
Arm J: Trastuzumab Emtansine + Atezolizumab
n=19 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation plus TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 mg/kg, as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm K: Ipatasertib + Atezolizumab
n=28 Participants
Participants with a positive tumor biomarker result for PIK3CA activating mutation received ipatasertib, 400 mg, orally QD in combination with atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm L: Ipatasertib + Atezolizumab
n=25 Participants
Participants with a positive tumor biomarker result for PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD and received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or intolerable toxicity, whichever occurs first.
|
Arm M: Ipatasertib + Paclitaxel
n=3 Participants
Participants with a positive tumor biomarker result for co-mutations in PIK3CA activating mutations and PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD on Days 1 to 21 of 28-day cycles and received paclitaxel, 80 mg/m\^2, as IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm N: Atezolizumab + Tiragolumab
n=23 Participants
Participants with a positive tumor biomarker result for TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by tiragolumab, 600 mg, as IV infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm O: Pralsetinib
n=3 Participants
Participants with a positive tumor biomarker result for RET gene fusion self-administered pralsetinib, 400 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PFS Rate at Month 3, 6, 9, and 12 as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
3 months
|
57.69 percent probability
Interval 38.7 to 76.68
|
50.00 percent probability
Interval 1.0 to 99.0
|
52.00 percent probability
Interval 32.42 to 71.58
|
52.17 percent probability
Interval 31.76 to 72.59
|
64.00 percent probability
Interval 45.18 to 82.82
|
41.03 percent probability
Interval 12.19 to 69.86
|
50.00 percent probability
Interval 15.35 to 84.65
|
48.13 percent probability
Interval 26.77 to 69.49
|
26.32 percent probability
Interval 6.52 to 46.12
|
35.56 percent probability
Interval 17.13 to 53.98
|
65.22 percent probability
Interval 45.75 to 84.68
|
66.67 percent probability
Interval 13.32 to 100.0
|
59.09 percent probability
Interval 38.55 to 79.64
|
66.67 percent probability
Interval 13.32 to 100.0
|
|
PFS Rate at Month 3, 6, 9, and 12 as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
6 months
|
37.09 percent probability
Interval 18.15 to 56.03
|
50.00 percent probability
Interval 1.0 to 99.0
|
36.00 percent probability
Interval 17.18 to 54.82
|
33.20 percent probability
Interval 13.48 to 52.92
|
44.00 percent probability
Interval 24.54 to 63.46
|
20.51 percent probability
Interval 0.0 to 45.25
|
12.50 percent probability
Interval 0.0 to 35.42
|
33.69 percent probability
Interval 13.43 to 53.95
|
10.53 percent probability
Interval 0.0 to 24.33
|
11.85 percent probability
Interval 0.0 to 24.41
|
33.82 percent probability
Interval 14.13 to 53.51
|
33.33 percent probability
Interval 0.0 to 86.68
|
40.91 percent probability
Interval 20.36 to 61.45
|
66.67 percent probability
Interval 13.32 to 100.0
|
|
PFS Rate at Month 3, 6, 9, and 12 as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
9 months
|
20.60 percent probability
Interval 4.61 to 36.59
|
25.00 percent probability
Interval 0.0 to 67.43
|
9.00 percent probability
Interval 0.0 to 20.78
|
28.46 percent probability
Interval 9.49 to 47.42
|
32.00 percent probability
Interval 13.71 to 50.29
|
10.26 percent probability
Interval 0.0 to 29.1
|
—
|
19.25 percent probability
Interval 2.32 to 36.18
|
10.53 percent probability
Interval 0.0 to 24.33
|
3.95 percent probability
Interval 0.0 to 11.53
|
24.15 percent probability
Interval 6.1 to 42.21
|
—
|
36.36 percent probability
Interval 16.26 to 56.46
|
—
|
|
PFS Rate at Month 3, 6, 9, and 12 as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
12 months
|
16.48 percent probability
Interval 1.79 to 31.17
|
—
|
4.50 percent probability
Interval 0.0 to 13.08
|
18.97 percent probability
Interval 2.39 to 35.56
|
23.33 percent probability
Interval 6.46 to 40.21
|
—
|
—
|
9.63 percent probability
Interval 0.0 to 22.3
|
—
|
—
|
14.49 percent probability
Interval 0.0 to 29.49
|
—
|
36.36 percent probability
Interval 16.26 to 56.46
|
—
|
SECONDARY outcome
Timeframe: Up to 32 monthsPopulation: Efficacy population included all participants who received at least one dose of study treatment and either had at least one post-baseline tumor assessment or discontinued treatment for any reason. Percentages have been rounded off to the nearest decimal point.
Disease control rate was defined as the percentage of participants whose best response was confirmed CR, confirmed PR, or a response of CR, PR, stable disease (SD), or non-CR/non-PD for a minimum of 98 days for 28-day cycle arms or 70 days for 21-day cycle arms after the first treatment date. CR \& PR were defined per RECIST/RANO as outlined in the description for the cORR OM. SD per RECIST: Neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. SD per RANO: Participant does not qualify for CR, PR, or minor response or PD; Stable non-enhancing (T2/FLAIR) lesions or abnormalities on same or lower dose of corticosteroids compared to baseline; No new lesions or new T2 or FLAIR abnormalities apart from those consistent with radiation effect, \& no new or increased enhancement; Participants on a should be corticosteroid dose that is not greater than dose at baseline scan \& is stable or improved clinically; Clinical status, stable/improved.
Outcome measures
| Measure |
Arm B: Inavolisib (GDC-0077)
n=26 Participants
Participants with a positive tumor biomarker result for PIK3CA activating mutation self-administered inavolisib 9 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
Arm C: Alectinib
n=5 Participants
Participants with a positive tumor biomarker result for ALK gene fusion self-administered alectinib, 600 mg, orally, BID until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm D: Ipatasertib
n=26 Participants
Participants with a positive tumor biomarker result for phosphatase and tensin homolog (PTEN) loss/loss-of-function or protein kinase B (AKT) activating mutation self-administered ipatasertib, 400 mg orally, QD until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm E: Atezolizumab + Chemotherapy
n=25 Participants
Participants with a positive tumor biomarker result for TMB-H or MSI-H or dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine) until disease progression, loss of clinical benefit, or unacceptable toxicity whichever occurs first.
|
Arm F: Trastuzumab Emtansine + Atezolizumab
n=25 Participants
Participants with a positive tumor biomarker result for human epidermal growth factor receptor 2 (HER2) gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 milligrams/kilograms (mg/kg), as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm G: PH FDC SC
n=13 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as subcutaneous (SC) injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2.
|
Arm H: PH FDC SC + Chemotherapy
n=8 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2 in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine).
|
Arm I: Trastuzumab Emtansine + Tucatinib
n=23 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received trastuzumab emtansine, 3.6 mg/kg as IV infusion, every 21 days in combination with tucatinib, 300 mg, orally, BID starting from Cycle 1 Day 1 until disease progression or unacceptable toxicity, whichever occurs first.
|
Arm J: Trastuzumab Emtansine + Atezolizumab
n=19 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation plus TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 mg/kg, as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm K: Ipatasertib + Atezolizumab
n=28 Participants
Participants with a positive tumor biomarker result for PIK3CA activating mutation received ipatasertib, 400 mg, orally QD in combination with atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm L: Ipatasertib + Atezolizumab
n=25 Participants
Participants with a positive tumor biomarker result for PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD and received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or intolerable toxicity, whichever occurs first.
|
Arm M: Ipatasertib + Paclitaxel
n=3 Participants
Participants with a positive tumor biomarker result for co-mutations in PIK3CA activating mutations and PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD on Days 1 to 21 of 28-day cycles and received paclitaxel, 80 mg/m\^2, as IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm N: Atezolizumab + Tiragolumab
n=23 Participants
Participants with a positive tumor biomarker result for TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by tiragolumab, 600 mg, as IV infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm O: Pralsetinib
n=3 Participants
Participants with a positive tumor biomarker result for RET gene fusion self-administered pralsetinib, 400 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants With Disease Control, as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
|
57.7 percentage of participants
Interval 36.9 to 76.6
|
40.0 percentage of participants
Interval 5.3 to 85.3
|
34.6 percentage of participants
Interval 17.2 to 55.7
|
32.0 percentage of participants
Interval 14.9 to 53.5
|
52.0 percentage of participants
Interval 31.3 to 72.2
|
23.1 percentage of participants
Interval 5.0 to 53.8
|
37.5 percentage of participants
Interval 8.5 to 75.5
|
26.1 percentage of participants
Interval 10.2 to 48.4
|
15.8 percentage of participants
Interval 3.4 to 39.6
|
10.7 percentage of participants
Interval 2.3 to 28.2
|
32.0 percentage of participants
Interval 14.9 to 53.5
|
66.7 percentage of participants
Interval 9.4 to 99.2
|
47.8 percentage of participants
Interval 26.8 to 69.4
|
66.7 percentage of participants
Interval 9.4 to 99.2
|
SECONDARY outcome
Timeframe: From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)Population: Safety evaluable population included all participants who received at least one dose of the study drug.
An AE is an untoward medical occurrence in participant administered a pharmaceutical product \& regardless of causal relationship with the product. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to it. AEs were graded for severity according to NCI CTCAE v5.0. Grade 1= Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated; Grade 2=Moderate; minimal, local or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living; Grade 3 = Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living; Grade 4= Life-threatening consequences/urgent intervention indicated; Grade 5= Death related to adverse event.
Outcome measures
| Measure |
Arm B: Inavolisib (GDC-0077)
n=26 Participants
Participants with a positive tumor biomarker result for PIK3CA activating mutation self-administered inavolisib 9 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
Arm C: Alectinib
n=5 Participants
Participants with a positive tumor biomarker result for ALK gene fusion self-administered alectinib, 600 mg, orally, BID until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm D: Ipatasertib
n=26 Participants
Participants with a positive tumor biomarker result for phosphatase and tensin homolog (PTEN) loss/loss-of-function or protein kinase B (AKT) activating mutation self-administered ipatasertib, 400 mg orally, QD until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm E: Atezolizumab + Chemotherapy
n=25 Participants
Participants with a positive tumor biomarker result for TMB-H or MSI-H or dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine) until disease progression, loss of clinical benefit, or unacceptable toxicity whichever occurs first.
|
Arm F: Trastuzumab Emtansine + Atezolizumab
n=25 Participants
Participants with a positive tumor biomarker result for human epidermal growth factor receptor 2 (HER2) gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 milligrams/kilograms (mg/kg), as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm G: PH FDC SC
n=13 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as subcutaneous (SC) injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2.
|
Arm H: PH FDC SC + Chemotherapy
n=8 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2 in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine).
|
Arm I: Trastuzumab Emtansine + Tucatinib
n=23 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received trastuzumab emtansine, 3.6 mg/kg as IV infusion, every 21 days in combination with tucatinib, 300 mg, orally, BID starting from Cycle 1 Day 1 until disease progression or unacceptable toxicity, whichever occurs first.
|
Arm J: Trastuzumab Emtansine + Atezolizumab
n=19 Participants
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation plus TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 mg/kg, as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm K: Ipatasertib + Atezolizumab
n=28 Participants
Participants with a positive tumor biomarker result for PIK3CA activating mutation received ipatasertib, 400 mg, orally QD in combination with atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm L: Ipatasertib + Atezolizumab
n=25 Participants
Participants with a positive tumor biomarker result for PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD and received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or intolerable toxicity, whichever occurs first.
|
Arm M: Ipatasertib + Paclitaxel
n=3 Participants
Participants with a positive tumor biomarker result for co-mutations in PIK3CA activating mutations and PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD on Days 1 to 21 of 28-day cycles and received paclitaxel, 80 mg/m\^2, as IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm N: Atezolizumab + Tiragolumab
n=23 Participants
Participants with a positive tumor biomarker result for TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by tiragolumab, 600 mg, as IV infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm O: Pralsetinib
n=3 Participants
Participants with a positive tumor biomarker result for RET gene fusion self-administered pralsetinib, 400 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With at Least One Adverse Event (AE) and Severity of AEs Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)
Any Adverse Event (AE), Any Grade
|
25 Participants
|
5 Participants
|
25 Participants
|
25 Participants
|
24 Participants
|
11 Participants
|
8 Participants
|
23 Participants
|
19 Participants
|
27 Participants
|
25 Participants
|
3 Participants
|
21 Participants
|
3 Participants
|
|
Number of Participants With at Least One Adverse Event (AE) and Severity of AEs Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)
Highest Severity: Grade 1 AEs
|
3 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
3 Participants
|
3 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With at Least One Adverse Event (AE) and Severity of AEs Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)
Highest Severity: Grade 2 AEs
|
14 Participants
|
2 Participants
|
14 Participants
|
9 Participants
|
10 Participants
|
6 Participants
|
3 Participants
|
11 Participants
|
7 Participants
|
7 Participants
|
11 Participants
|
0 Participants
|
11 Participants
|
0 Participants
|
|
Number of Participants With at Least One Adverse Event (AE) and Severity of AEs Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)
Highest Severity: Grade 3 AEs
|
6 Participants
|
2 Participants
|
9 Participants
|
11 Participants
|
11 Participants
|
2 Participants
|
4 Participants
|
7 Participants
|
11 Participants
|
16 Participants
|
10 Participants
|
3 Participants
|
8 Participants
|
2 Participants
|
|
Number of Participants With at Least One Adverse Event (AE) and Severity of AEs Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)
Highest Severity: Grade 4 AEs
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With at Least One Adverse Event (AE) and Severity of AEs Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)
Highest Severity: Grade 5 AEs
|
2 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
Adverse Events
Arm B: Inavolisib (GDC-0077)
Serious events: 5 serious events
Other events: 25 other events
Deaths: 19 deaths
Arm C: Alectinib
Serious events: 2 serious events
Other events: 5 other events
Deaths: 1 deaths
Arm D: Ipatasertib
Serious events: 6 serious events
Other events: 25 other events
Deaths: 16 deaths
Arm E: Atezolizumab + Chemotherapy
Serious events: 11 serious events
Other events: 25 other events
Deaths: 16 deaths
Arm F: Trastuzumab Emtansine + Atezolizumab
Serious events: 9 serious events
Other events: 23 other events
Deaths: 16 deaths
Arm G: PH FDC SC
Serious events: 2 serious events
Other events: 11 other events
Deaths: 6 deaths
Arm H: PH FDC SC + Chemotherapy
Serious events: 2 serious events
Other events: 8 other events
Deaths: 8 deaths
Arm I: Trastuzumab Emtansine + Tucatinib
Serious events: 6 serious events
Other events: 23 other events
Deaths: 14 deaths
Arm J: Trastuzumab Emtansine + Atezolizumab
Serious events: 7 serious events
Other events: 19 other events
Deaths: 16 deaths
Arm K: Ipatasertib + Atezolizumab
Serious events: 10 serious events
Other events: 26 other events
Deaths: 22 deaths
Arm L: Ipatasertib + Atezolizumab
Serious events: 8 serious events
Other events: 25 other events
Deaths: 10 deaths
Arm M: Ipatasertib + Paclitaxel
Serious events: 2 serious events
Other events: 3 other events
Deaths: 2 deaths
Arm N: Atezolizumab + Tiragolumab
Serious events: 6 serious events
Other events: 21 other events
Deaths: 10 deaths
Arm O: Pralsetinib
Serious events: 2 serious events
Other events: 3 other events
Deaths: 1 deaths
Serious adverse events
| Measure |
Arm B: Inavolisib (GDC-0077)
n=26 participants at risk
Participants with a positive tumor biomarker result for PIK3CA activating mutation self-administered inavolisib 9 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
Arm C: Alectinib
n=5 participants at risk
Participants with a positive tumor biomarker result for ALK gene fusion self-administered alectinib, 600 mg, orally, BID until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm D: Ipatasertib
n=26 participants at risk
Participants with a positive tumor biomarker result for phosphatase and tensin homolog (PTEN) loss/loss-of-function or protein kinase B (AKT) activating mutation self-administered ipatasertib, 400 mg orally, QD until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm E: Atezolizumab + Chemotherapy
n=25 participants at risk
Participants with a positive tumor biomarker result for TMB-H or MSI-H or dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine) until disease progression, loss of clinical benefit, or unacceptable toxicity whichever occurs first.
|
Arm F: Trastuzumab Emtansine + Atezolizumab
n=25 participants at risk
Participants with a positive tumor biomarker result for human epidermal growth factor receptor 2 (HER2) gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 milligrams/kilograms (mg/kg), as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm G: PH FDC SC
n=13 participants at risk
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as subcutaneous (SC) injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2.
|
Arm H: PH FDC SC + Chemotherapy
n=8 participants at risk
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2 in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine).
|
Arm I: Trastuzumab Emtansine + Tucatinib
n=23 participants at risk
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received trastuzumab emtansine, 3.6 mg/kg as IV infusion, every 21 days in combination with tucatinib, 300 mg, orally, BID starting from Cycle 1 Day 1 until disease progression or unacceptable toxicity, whichever occurs first.
|
Arm J: Trastuzumab Emtansine + Atezolizumab
n=19 participants at risk
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation plus TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 mg/kg, as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm K: Ipatasertib + Atezolizumab
n=28 participants at risk
Participants with a positive tumor biomarker result for PIK3CA activating mutation received ipatasertib, 400 mg, orally QD in combination with atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm L: Ipatasertib + Atezolizumab
n=25 participants at risk
Participants with a positive tumor biomarker result for PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD and received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or intolerable toxicity, whichever occurs first.
|
Arm M: Ipatasertib + Paclitaxel
n=3 participants at risk
Participants with a positive tumor biomarker result for co-mutations in PIK3CA activating mutations and PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD on Days 1 to 21 of 28-day cycles and received paclitaxel, 80 mg/m\^2, as IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm N: Atezolizumab + Tiragolumab
n=23 participants at risk
Participants with a positive tumor biomarker result for TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by tiragolumab, 600 mg, as IV infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm O: Pralsetinib
n=3 participants at risk
Participants with a positive tumor biomarker result for RET gene fusion self-administered pralsetinib, 400 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Perirectal abscess
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Cardiac disorders
Supraventricular tachycardia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Enteritis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Gastrointestinal fistula
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Asthenia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Chest pain
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Fatigue
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Pyrexia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Hepatobiliary disorders
Acute hepatic failure
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Abdominal infection
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
COVID-19
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Clostridium difficile infection
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Colonic abscess
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Coronavirus infection
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Gangrene
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Oesophageal candidiasis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Peritonitis bacterial
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Pneumonia
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Pyelonephritis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Sepsis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Septic shock
|
3.8%
1/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Urosepsis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Wound infection
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Femur fracture
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Platelet count decreased
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Dehydration
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Failure to thrive
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Musculoskeletal and connective tissue disorders
Haemarthrosis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Musculoskeletal and connective tissue disorders
Spinal stenosis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Brain oedema
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Cerebrovascular accident
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Embolic stroke
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Seizure
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Product Issues
Device breakage
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Product Issues
Device malfunction
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Product Issues
Device occlusion
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Renal and urinary disorders
Urinary tract obstruction
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Vascular disorders
Arterial haemorrhage
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Vascular disorders
Peripheral vascular disorder
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
Other adverse events
| Measure |
Arm B: Inavolisib (GDC-0077)
n=26 participants at risk
Participants with a positive tumor biomarker result for PIK3CA activating mutation self-administered inavolisib 9 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
Arm C: Alectinib
n=5 participants at risk
Participants with a positive tumor biomarker result for ALK gene fusion self-administered alectinib, 600 mg, orally, BID until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm D: Ipatasertib
n=26 participants at risk
Participants with a positive tumor biomarker result for phosphatase and tensin homolog (PTEN) loss/loss-of-function or protein kinase B (AKT) activating mutation self-administered ipatasertib, 400 mg orally, QD until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm E: Atezolizumab + Chemotherapy
n=25 participants at risk
Participants with a positive tumor biomarker result for TMB-H or MSI-H or dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine) until disease progression, loss of clinical benefit, or unacceptable toxicity whichever occurs first.
|
Arm F: Trastuzumab Emtansine + Atezolizumab
n=25 participants at risk
Participants with a positive tumor biomarker result for human epidermal growth factor receptor 2 (HER2) gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 milligrams/kilograms (mg/kg), as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm G: PH FDC SC
n=13 participants at risk
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as subcutaneous (SC) injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2.
|
Arm H: PH FDC SC + Chemotherapy
n=8 participants at risk
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received PH FDC SC, a loading dose of 1200 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of Cycle 1 followed by a maintenance dose of 600 mg pertuzumab + 600 mg trastuzumab as a SC injection on Day 1 of each 21-day cycle, starting at Cycle 2 in combination with investigators choice of chemotherapy (docetaxel, paclitaxel, or capecitabine).
|
Arm I: Trastuzumab Emtansine + Tucatinib
n=23 participants at risk
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation without known TMB-H/ MSI-H/ dMMR received trastuzumab emtansine, 3.6 mg/kg as IV infusion, every 21 days in combination with tucatinib, 300 mg, orally, BID starting from Cycle 1 Day 1 until disease progression or unacceptable toxicity, whichever occurs first.
|
Arm J: Trastuzumab Emtansine + Atezolizumab
n=19 participants at risk
Participants with a positive tumor biomarker result for HER2 gene amplification or mutation plus TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by trastuzumab emtansine, 3.6 mg/kg, as IV infusion, every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm K: Ipatasertib + Atezolizumab
n=28 participants at risk
Participants with a positive tumor biomarker result for PIK3CA activating mutation received ipatasertib, 400 mg, orally QD in combination with atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm L: Ipatasertib + Atezolizumab
n=25 participants at risk
Participants with a positive tumor biomarker result for PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD and received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or intolerable toxicity, whichever occurs first.
|
Arm M: Ipatasertib + Paclitaxel
n=3 participants at risk
Participants with a positive tumor biomarker result for co-mutations in PIK3CA activating mutations and PTEN loss/loss-of-function or AKT-activating mutation self-administered ipatasertib, 400 mg, orally, QD on Days 1 to 21 of 28-day cycles and received paclitaxel, 80 mg/m\^2, as IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, or consent withdrawal, whichever occurs first.
|
Arm N: Atezolizumab + Tiragolumab
n=23 participants at risk
Participants with a positive tumor biomarker result for TMB-H/ MSI-H/ dMMR received atezolizumab, 1200 mg, as IV infusion, on Day 1 of each 21-day cycle, followed by tiragolumab, 600 mg, as IV infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity, whichever occurs first.
|
Arm O: Pralsetinib
n=3 participants at risk
Participants with a positive tumor biomarker result for RET gene fusion self-administered pralsetinib, 400 mg, orally, QD until disease progression, intolerable toxicity, or consent withdrawal whichever occurs first.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Infections and infestations
Tinea infection
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Upper respiratory tract infection
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Urinary tract infection
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
40.0%
2/5 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
11.5%
3/26 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
16.0%
4/25 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
17.4%
4/23 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.7%
3/28 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Accidental overdose
|
3.8%
1/26 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Skin infection
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Pneumonia
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.7%
3/28 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Blood and lymphatic system disorders
Anaemia
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
2/26 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
5/25 • Number of events 7 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
5/25 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
15.4%
2/13 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
21.7%
5/23 • Number of events 7 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.7%
3/28 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
100.0%
3/3 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
26.1%
6/23 • Number of events 7 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
66.7%
2/3 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
3.8%
1/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
13.0%
3/23 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Blood and lymphatic system disorders
Thrombocytosis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.5%
2/19 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Eye disorders
Dry eye
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Eye disorders
Lacrimation increased
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
16.0%
4/25 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Eye disorders
Periorbital oedema
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Eye disorders
Vision blurred
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Eye disorders
Visual impairment
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Abdominal distension
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Abdominal hernia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Abdominal pain
|
23.1%
6/26 • Number of events 7 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
11.5%
3/26 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
15.4%
2/13 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.5%
2/19 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
14.3%
4/28 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
17.4%
4/23 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Anal incontinence
|
3.8%
1/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Ascites
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.5%
2/19 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Constipation
|
15.4%
4/26 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
15.4%
4/26 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
16.0%
4/25 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
24.0%
6/25 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
25.0%
2/8 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
17.4%
4/23 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.7%
3/28 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
100.0%
3/3 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
30.4%
7/23 • Number of events 9 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Dental caries
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Diarrhoea
|
23.1%
6/26 • Number of events 7 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
73.1%
19/26 • Number of events 35 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
64.0%
16/25 • Number of events 20 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
38.5%
5/13 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
37.5%
3/8 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
34.8%
8/23 • Number of events 13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
15.8%
3/19 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
64.3%
18/28 • Number of events 30 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
72.0%
18/25 • Number of events 23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
100.0%
3/3 • Number of events 7 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
17.4%
4/23 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
66.7%
2/3 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Dry mouth
|
19.2%
5/26 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
13.0%
3/23 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Dysphagia
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Flatulence
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
19.2%
5/26 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
25.0%
2/8 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Haematochezia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Haemorrhoidal haemorrhage
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Nausea
|
26.9%
7/26 • Number of events 8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
40.0%
2/5 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
50.0%
13/26 • Number of events 15 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
32.0%
8/25 • Number of events 10 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
24.0%
6/25 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
15.4%
2/13 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
47.8%
11/23 • Number of events 15 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
31.6%
6/19 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
46.4%
13/28 • Number of events 16 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
44.0%
11/25 • Number of events 11 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
100.0%
3/3 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
43.5%
10/23 • Number of events 11 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Oesophagitis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Stomatitis
|
19.2%
5/26 • Number of events 8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
16.0%
4/25 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
13.0%
3/23 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
21.1%
4/19 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
14.3%
4/28 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
66.7%
2/3 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Gastrointestinal disorders
Vomiting
|
11.5%
3/26 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
23.1%
6/26 • Number of events 9 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
16.0%
4/25 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
30.4%
7/23 • Number of events 8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
15.8%
3/19 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
32.1%
9/28 • Number of events 10 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
24.0%
6/25 • Number of events 7 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
17.4%
4/23 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Asthenia
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Chills
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.5%
2/19 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Fatigue
|
34.6%
9/26 • Number of events 9 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
19.2%
5/26 • Number of events 7 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
52.0%
13/25 • Number of events 17 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
52.0%
13/25 • Number of events 17 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
30.8%
4/13 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
52.2%
12/23 • Number of events 13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
42.1%
8/19 • Number of events 9 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
32.1%
9/28 • Number of events 11 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
48.0%
12/25 • Number of events 13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
100.0%
3/3 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
26.1%
6/23 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Gait disturbance
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Influenza like illness
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Injection site reaction
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
15.4%
2/13 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Localised oedema
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Mass
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Non-cardiac chest pain
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Oedema
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Oedema peripheral
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
15.8%
3/19 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.7%
3/28 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
17.4%
4/23 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Pain
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.7%
3/28 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Performance status decreased
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Peripheral swelling
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
General disorders
Pyrexia
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
21.1%
4/19 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
66.7%
2/3 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
COVID-19
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
13.0%
3/23 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.5%
2/19 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
17.4%
4/23 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Candida infection
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Colonic abscess
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Cystitis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Otitis media
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Infections and infestations
Penile infection
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Fall
|
3.8%
1/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
16.0%
4/25 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Incorrect dose administered
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
24.0%
6/25 • Number of events 7 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
21.1%
4/19 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Injection related reaction
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Limb injury
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Overdose
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Post procedural haemorrhage
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Underdose
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
15.4%
4/26 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
13.0%
3/23 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Injury, poisoning and procedural complications
Vascular access complication
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
5/25 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
26.1%
6/23 • Number of events 10 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
66.7%
2/3 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
13.0%
3/23 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Aspartate aminotransferase increased
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
11.5%
3/26 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
28.0%
7/25 • Number of events 9 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
47.8%
11/23 • Number of events 22 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
15.8%
3/19 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
66.7%
2/3 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
13.0%
3/23 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Blood albumin decreased
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
13.0%
3/23 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.7%
3/28 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Blood bicarbonate decreased
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Blood bilirubin increased
|
3.8%
1/26 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Blood creatinine decreased
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
13.0%
3/23 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Blood glucose increased
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Blood iron decreased
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Cardiac murmur
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Ejection fraction decreased
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Neutrophil count increased
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Occult blood
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Platelet count decreased
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
17.4%
4/23 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
21.1%
4/19 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Weight decreased
|
15.4%
4/26 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
16.0%
4/25 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.7%
3/28 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Investigations
Weight increased
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
11.5%
3/26 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
23.1%
6/26 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
16.0%
4/25 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
26.1%
6/23 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
36.8%
7/19 • Number of events 8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
32.1%
9/28 • Number of events 11 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Dehydration
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
19.2%
5/26 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
32.0%
8/25 • Number of events 9 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
16.0%
4/25 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
13.0%
3/23 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
26.3%
5/19 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
21.4%
6/28 • Number of events 7 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
36.0%
9/25 • Number of events 10 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
66.7%
2/3 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
26.1%
6/23 • Number of events 12 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
46.2%
12/26 • Number of events 17 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
19.2%
5/26 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
17.9%
5/28 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
24.0%
6/25 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.5%
2/19 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
21.1%
4/19 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
3.8%
1/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.5%
2/19 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Hypovolaemia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Iron deficiency
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Metabolism and nutrition disorders
Obesity
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
11.5%
3/26 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
19.2%
5/26 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.5%
2/19 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.7%
3/28 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
11.5%
3/26 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
13.0%
3/23 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
16.0%
4/25 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
17.9%
5/28 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
13.0%
3/23 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
14.3%
4/28 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Brain oedema
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Cognitive disorder
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
11.5%
3/26 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
16.0%
4/25 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
17.4%
4/23 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Dysgeusia
|
23.1%
6/26 • Number of events 6 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Headache
|
3.8%
1/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
40.0%
2/5 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
17.4%
4/23 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Neuralgia
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.5%
2/19 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Paraesthesia
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.5%
2/19 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
3.8%
1/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
66.7%
2/3 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Syncope
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Toxic encephalopathy
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Nervous system disorders
Tremor
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Psychiatric disorders
Depression
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
13.0%
3/23 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Renal and urinary disorders
Dysuria
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.1%
2/28 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
16.0%
4/25 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Reproductive system and breast disorders
Pelvic pain
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Reproductive system and breast disorders
Vaginal cyst
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Aphonia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
16.0%
4/25 • Number of events 9 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
15.8%
3/19 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.7%
3/28 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
17.4%
4/23 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
7.7%
2/26 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
20.0%
1/5 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.7%
3/28 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.7%
2/23 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Cold sweat
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Decubitus ulcer
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.5%
2/19 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Nail disorder
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Onychoclasis
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysaesthesia syndrome
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
24.0%
6/25 • Number of events 7 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.0%
3/25 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
30.4%
7/23 • Number of events 8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.7%
3/28 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
13.0%
3/23 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
11.5%
3/26 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
16.0%
4/25 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
17.4%
4/23 • Number of events 5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
25.0%
7/28 • Number of events 9 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
16.0%
4/25 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
26.1%
6/23 • Number of events 8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Skin fissures
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Skin hyperpigmentation
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Skin and subcutaneous tissue disorders
Skin weeping
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
5.3%
1/19 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Vascular disorders
Flushing
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/28 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Vascular disorders
Hot flush
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
12.5%
1/8 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Vascular disorders
Hypertension
|
0.00%
0/26 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.8%
1/26 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/25 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/13 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/19 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
3.6%
1/28 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.3%
1/23 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
|
Vascular disorders
Hypotension
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/5 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
2/26 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
4.0%
1/25 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
7.7%
1/13 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/8 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
10.5%
2/19 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
14.3%
4/28 • Number of events 4 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
8.0%
2/25 • Number of events 2 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
66.7%
2/3 • Number of events 3 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
0.00%
0/23 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
33.3%
1/3 • Number of events 1 • From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Safety evaluable population included all participants who received at least one dose of the study drug.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
- Publication restrictions are in place
Restriction type: OTHER